source
- Marrow Therapeutics raises $173M to develop bone-marrow-targeted gene therapies for blood disordersMarrow Therapeutics announced a $173 million financing round, combining a $53 million Series A led by founder Scion Life Sciences and venBio with a $120 million Series B led by OrbiMed. The compan…
- Marrow Therapeutics secures $173 million to advance siRNA therapy for sickle cell, targeting CRISPR competitionMarrow Therapeutics announced a $173 million financing round to fund development of its siRNA drug aimed at treating sickle cell disease. The funding comes after FDA approval of two gene therapies…